Loading quotes...

Forecast

The analysts' average price target is €132.37 (+7.92%). The median is €133.86 (+9.14%).

Buy	8
Hold	7
Sell	3

News Go to news feed

AptarGroup: new management emphasizes execution after strong pharma growth

At the Wells Fargo Healthcare Conference, AptarGroup under new CEO Gael Touya highlighted execution as a priority and confirmed solid growth in its pharma business and in injection systems. The company sees long‑term opportunities in intranasal delivery, GLP‑1 research and OTC switches, but conceded operational issues in the North American beauty segment and production/maintenance shortfalls. A destocking of emergency medicines hit the first half by $65–70 million, is expected to be mostly resolved by Q4 and should improve the margin base for 2027. » More on de.investing.com
Dermalogica uses AptarGroups' NeoDropper dosing technology in FutureCode Booster serum

Dermalogica is using AptarGroups' NeoDropper autoload pipette technology for its new FutureCode Booster serum. The system combines a twist-and-press delivery mechanism with an automatic reload system. The design is intended to reduce breakage risk, minimize product loss and was praised by consumers for dosing performance and ease of use. The product launch expands the existing partnership with Aptar, which previously supplied recyclable dosing solutions to Dermalogica. » More on de.investing.com
AptarGroup pays quarterly dividend of $0.48

AptarGroup announced a quarterly cash dividend of $0.48 per share, payable August 20, 2026 to shareholders of record on July 30, 2026. According to the data, the company has increased its dividend for 33 consecutive years; the current dividend yield is 1.49%. AptarGroup is rated as undervalued and will hold a conference call on July 31, 2026 to discuss Q2 results. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, AptarGroup has already paid €1.23 in dividends. The last payout was in August.

Financials

In the last quarter, AptarGroup had revenue of €899.73M and net profit of €28.78M

(EUR)	September 2026	YoY
Revenue	899.73M	9.86%
Gross profit	262.54M	7.03%
Net profit	28.78M	73.60%
EBITDA	133.9M	35.31%

Fundamentals

Metric	Value
Market capitalization	€7.78B
Number of shares	63.58M
52-week high/low	€131.10 - €92.12
Dividend yield	1.34%
Dividends TTM	€1.64
Beta	0.34
P/E ratio	32.98
PEG ratio	-0.96
P/B ratio	3.33
P/S ratio	2.19

Company profile

AptarGroup, Inc. provides a range of dispensing, sealing, and material science solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectable, and food and beverage markets. The company operates through three segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma segment provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases in pharmaceutical market; elastomer for injectable primary packaging components; and active material science solutions. The Beauty + Home segment primarily sells pumps, closures, aerosol valves, accessories, and sealing solutions to the personal care and home care markets; and pumps and decorative components to the beauty market. The Food + Beverage segment offers dispensing and non-dispensing closures, elastomeric flow control components, spray pumps, and aerosol valves to the food and beverage markets. It sells its products through own sales force, as well as independent representatives and distributors in Asia, Europe, Latin America, and North America. The company has a strategic partnership with PureCycle Technologies LLC to develop ultra-pure recycled polypropylene into dispensing applications; and a collaboration with Sonmol for developing a digital therapies and services platform targeting respiratory and other diseases. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.